Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Apalutamide Tablet Formulations
NCT02160756Phase 1Completed
- Sponsor
- Aragon Pharmaceuticals
- Start
- Jun 2014
- Primary completion
- Nov 2014
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of apalutamide in prostate cancer (PCa) (4 arms), sponsored by Aragon Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration, Time to Reach Maximum Concentration and 3 more. Started Jun 2014; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02160756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02160756.